-
Mashup Score: 3Benjamin Besse on NSCLC A Vaccine Under Study to Treat Advanced Disease - The ASCO Post - 3 year(s) ago
ESMO Congress 2021 Benjamin Besse, MD, PhD, of the Institut Gustave Roussy, discusses final phase III findings from the Atalante-1 trial, which explored the question of whether the OSE2101 vaccine is more beneficial than standard treatment for patients with HLA-A2–positive non–small cell lung cancer after immune checkpoint inhibitors…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Copanlisib Plus Rituximab Yields Large PFS Benefit in MZL - 3 year(s) ago
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death relative to rituximab alone in a subset analysis of the phase 3 CHRONOS trial.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death. https://t.co/G77vlKArCF #copanlisib #rituximab #lymphoma #ESMO2021
-
-
Mashup Score: 0Copanlisib Plus Rituximab Yields Large PFS Benefit in MZL - 3 year(s) ago
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death relative to rituximab alone in a subset analysis of the phase 3 CHRONOS trial.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death. https://t.co/G77vlKArCF #copanlisib #rituximab #lymphoma #ESMO2021
-
-
Mashup Score: 0Copanlisib Plus Rituximab Yields Large PFS Benefit in MZL - 3 year(s) ago
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death relative to rituximab alone in a subset analysis of the phase 3 CHRONOS trial.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death. https://t.co/G77vlKArCF #copanlisib #rituximab #lymphoma #ESMO2021
-
-
Mashup Score: 0Copanlisib Plus Rituximab Yields Large PFS Benefit in MZL - 3 year(s) ago
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death relative to rituximab alone in a subset analysis of the phase 3 CHRONOS trial.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death. https://t.co/G77vlKArCF #copanlisib #rituximab #lymphoma #ESMO2021
-
-
Mashup Score: 0
New analyses from the PEACE-1 and STAMPEDE multicenter trials demonstrated that the addition of abiraterone acetate plus prednisolone to standard-of-care therapy improves survival in castration-sensitive prostate cancer.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Analysis of prostate cancer trials data demonstrated that the addition of abiraterone acetate plus prednisolone to standard-of-care therapy improves survival. https://t.co/d9ZRRUTl74 @MDAndersonNews #prostatecancer #ESMO2021
-
-
Mashup Score: 1Copanlisib Plus Rituximab Yields Large PFS Benefit in MZL - 3 year(s) ago
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death relative to rituximab alone in a subset analysis of the phase 3 CHRONOS trial.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% reduction in the risk for progression or death. https://t.co/G77vlKArCF #copanlisib #rituximab #lymphoma #ESMO2021
-
-
Mashup Score: 2
For second-line treatment of metastatic HER2-positive breast cancer, the new-generation antibody drug conjugate (ADC) trastuzumab deruxtecan-nxki (T-DXd) is far more effective than the older-generation ADC trastuzumab emtansine (T-DM1), according to data from the first head-to-head comparison of ADCs for any malignancy, not just breast cancer.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Data from the first head-to-head comparison of antibody drug conjugate’s found the new-generation more effective for metastatic breast cancer. https://t.co/VgU0wOD3DZ @JavierCortesMD @sloan_kettering #breastcancer #ESMO2021
-
-
Mashup Score: 3
New analyses from the PEACE-1 and STAMPEDE multicenter trials demonstrated that the addition of abiraterone acetate plus prednisolone to standard-of-care therapy improves survival in castration-sensitive prostate cancer.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Analysis of prostate cancer trials data demonstrated that the addition of abiraterone acetate plus prednisolone to standard-of-care therapy improves survival. https://t.co/d9ZRRUTl74 @MDAndersonNews #prostatecancer #ESMO2021
-
-
Mashup Score: 2
New analyses from the PEACE-1 and STAMPEDE multicenter trials demonstrated that the addition of abiraterone acetate plus prednisolone to standard-of-care therapy improves survival in castration-sensitive prostate cancer.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Analysis of prostate cancer trials data demonstrated that the addition of abiraterone acetate plus prednisolone to standard-of-care therapy improves survival. https://t.co/d9ZRRUTl74 @MDAndersonNews #prostatecancer #ESMO2021
-
Benjamin Besse, MD, PhD, on NSCLC: A Vaccine Under Study to Treat Advanced Disease https://t.co/DDZxnWDjmB #LCSM #ESMO21 #ESMO2021 @BenjaminBesseMD @GustaveRoussy https://t.co/WPwo43A5DH